Investors – SynAct Pharma

A MESSAGE FROM OUR CEO

”SynAct is in a strong financial position with a strong pipeline, and we are all grateful for the support and look forward to the second half of the year.”

Press releases

August 5, 2022 Regulatory
SynAct Pharma publishes Q2 2022 interim report
July 21, 2022 Non Regulatory
SynAct Pharma improves the design of the ongoing Phase 2a study in iMN

All press releases

Calendar

04

Nov

November 4, 2022

Interim Report Q3 2022
Add to calendar
17

Feb

February 17, 2023

Annual Results 2022
Add to calendar

All calendar events

Reports

August 5, 2022 Regulatory
SynAct Pharma publishes Q2 2022 interim report
May 30, 2022 Regulatory
SynAct Pharma publishes Q1 2022 interim report

All Reports

The share